Rubicon Research is an IP led, specialty pharmaceutical company focused on our mission to provide innovative yet affordable patient-centered products and solutions so as to address unmet needs around the world. We leverage our proprietary technologies and specialized formulation development skills to provide solutions to complex delivery challenges; enabling better patient outcomes.
Our portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, topical, drug device combinations and fixed-dose combinations. We hold more than 50 issued patents in drug delivery technologies, and have launched over 64 SKUs, with over 1.3+ billion extended units sold in the US in 2020. In the pipeline are 10+ approvals and launches (across oral solids and ophthalmic formulations) slated for 2021. Additionally, there are more than 130 products in development and 22 filed products under review with the US FDA.
Founded in 1999, Rubicon Research started operations in 2000 as India’s first independent product development company, establishing itself as a well-recognized outsourcing partner to the global healthcare and pharmaceutical industry. Over the last 20 years, Rubicon Research has expanded its development expertise with a commercial focus, leading to multiple product approvals and launches. The manufacturing facility located in Ambernath, India, has global regulatory approvals for commercial supply of oral solid dosage forms.
2019 was an eventful year for Rubicon Research. We received a USD 100 million growth capital commitment from General Atlantic and acquired 15 ANDAs to augment our fast-growing generic portfolio. With General Atlantic’s support, Rubicon Research is expanding its R&D program and building a larger, globalized manufacturing footprint. As part of our ongoing effort to establish a global development network, Rubicon Research acquired Impopharma Canada Ltd in late 2019, and established Rubicon Research Canada Ltd. Our Canadian development facility specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, OTC, and dermal products.
In 2020, Rubicon Research launched Rubicon Consumer Healthcare, a subsidiary that develops self-care products and solutions in the personal wellness space, for the Indian market. The company translates Rubicon Research’s 20 years of global pharmaceutical expertise into innovative, easy-to-use consumer products that are focused on improving overall wellness.
Later in 2020, we also launched Rubicon Academy, a learning platform for pharmaceutical professionals and students. The academy aims to provide industry-relevant learning experiences to bridge the skill gap between education and employment, and build a highly skilled workforce.
In 2021 we acquired an outstanding oral liquid and nasal product manufacturing facility in Satara, Maharashtra, to advance our capabilities and widen our portfolio.
Rubicon Research operates out of five locations—the corporate HQ and R&D center in Thane, India, the R&D center in Concord, Canada, the manufacturing sites in Ambernath and Satara, India, and the business development and regulatory office in Plainsboro, US.
To know more about our infrastructure visit our Operations page.